Cargando…

Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain

PURPOSE: To describe the efficacy and safety of hydromorphone extended-release tablets (OROS hydromorphone ER) during dose conversion and titration. PATIENTS AND METHODS: A total of 459 opioid-tolerant adults with chronic moderate to severe low back pain participated in an open-label, 2- to 4-week c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hale, Martin E, Nalamachu, Srinivas R, Khan, Arif, Kutch, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645948/ https://www.ncbi.nlm.nih.gov/pubmed/23658495 http://dx.doi.org/10.2147/JPR.S39980

Ejemplares similares

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study
por: Wallace, M, et al.
Publicado: (2007)

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
por: Park, Cheol Kyu, et al.
Publicado: (2016)

A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
por: Weinstein, Sharon M
Publicado: (2009)

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
por: Devarakonda, Krishna, et al.
Publicado: (2013)

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(® )hydromorphone in patients with chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2009)

Opioid rotation with extended-release opioids: where should we begin?
por: Nalamachu, Srinivas
Publicado: (2011)

A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS(®)) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study
por: Song, Eun-Kee, et al.
Publicado: (2015)

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Pharmacokinetic profile of a 24-hour controlled-release OROS(® )formulation of hydromorphone in the presence and absence of food
por: Sathyan, Gayatri, et al.
Publicado: (2007)

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
por: Philis-Tsimikas, Athena, et al.
Publicado: (2013)

Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia
por: Irving, Gordon A, et al.
Publicado: (2012)

Morphine versus Hydromorphone: Does Choice of Opioid Influence Outcomes?
por: Gulur, Padma, et al.
Publicado: (2015)

Hydromorphone-Induced Tactile Hallucinations: Rare Opioid Side Effect
por: Kiyokawa, Miki, et al.
Publicado: (2021)

A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2008)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Influence of anatomic location of lidocaine patch 5% on effectiveness and tolerability for postherpetic neuralgia
por: Nalamachu, Srinivas, et al.
Publicado: (2013)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids
por: Oldenmenger, Wendy H., et al.
Publicado: (2011)

Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
por: Shin, Seong Hoon, et al.
Publicado: (2014)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
por: Pape, Lars, et al.
Publicado: (2011)

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2019)

Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
por: Gaber, A. Osama, et al.
Publicado: (2013)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen, Jie, et al.
Publicado: (2017)

Once‐ and twice‐daily heat acclimation confer similar heat adaptations, inflammatory responses and exercise tolerance improvements
por: Willmott, Ashley G. B., et al.
Publicado: (2018)

Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing
por: Buaboonnam, Jassada, et al.
Publicado: (2021)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
por: Beeh, Kai M, et al.
Publicado: (2012)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Publicado: (2018)

Update on the clinical utility of once-daily tacrolimus in the management of transplantation
por: Posadas Salas, Maria Aurora, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ivn3gbl3mfrsuq8pvpk80h7ebe